NSRX
Nasus Pharma Ltd. AMEX$2.70
Mkt Cap $23.3M
52w Low $1.98
9.0% of range
52w High $9.99
50d MA $3.35
200d MA $6.17
P/E (TTM)
-16.2x
EV/EBITDA
0.0x
P/B
—
Debt/Equity
0.0x
ROE
-211.6%
P/FCF
0.0x
RSI (14)
—
ATR (14)
—
Beta
5.02
50d MA
$3.35
200d MA
$6.17
Avg Volume
193.0K
About
Nasus Pharma is a clinical-stage specialty pharmaceutical company focused primarily on the development of intranasal drugs to treat emergency medical conditions such as severe allergies, anaphylaxis, and opioid overdose. Their lead products include NS002, an intranasal powder epinephrine nasal spray for type 1 severe allergies and anaphylaxis, and NS001, an intranasal naloxone powder spray for opi…
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 26 | Citizens | Maintains | Market Outperform → Market Outperform | — | $2.76 | $2.53 | -8.3% | -13.0% | -19.9% | -27.2% | -19.6% | -7.6% |
Data updated apr 26, 2026 3:51pm
· Source: massive.com